Skip to main content

Table 1 Participants will be eligible if they meet the following criteria

From: Cholinesterase inhibitor to prevent falls in Parkinson’s disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s disease

Inclusion criteria
a Diagnosis of idiopathic Parkinson’s disease.
b Modified Hoehn and Yahr stage 1 to 4 disease [21].
c Have experienced a fall in the previous year.
d Able to walk ≥10 m without aids or assistance.
e 18+ years of age
Exclusion criteria
a Previous ChEi use during the 12 months prior to enrolment.
b Hypersensitivity to rivastigmine
c Dementia diagnosed according to Movement Disorder Society (MDS) criteria [22]
d Inability to attend or comply with treatment or follow-up scheduling.
e Non-English-speaking as the cognitive tests are performed in English.
f Falling ≥4x per day.
g Unwillingness to use an acceptable method of contraception for the duration of the trial if they are of childbearing potential.
h Pregnant and/or breast feeding